KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Interest Expenses (2019 - 2025)

Rigel Pharmaceuticals has reported Interest Expenses over the past 9 years, most recently at $1.7 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 13.09% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $7.3 million, down 7.55%, while the annual FY2025 figure was $7.3 million, 7.55% down from the prior year.
  • Interest Expenses for Q4 2025 was $1.7 million at Rigel Pharmaceuticals, down from $1.9 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $2.1 million in Q3 2024 and troughed at $485000.0 in Q1 2021.
  • A 5-year average of $1.5 million and a median of $1.8 million in 2021 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: soared 398.3% in 2021 and later plummeted 67.65% in 2022.
  • Year by year, Interest Expenses stood at $1.3 million in 2021, then decreased by 14.78% to $1.1 million in 2022, then skyrocketed by 72.27% to $1.9 million in 2023, then rose by 2.52% to $2.0 million in 2024, then decreased by 13.09% to $1.7 million in 2025.
  • Business Quant data shows Interest Expenses for RIGL at $1.7 million in Q4 2025, $1.9 million in Q3 2025, and $1.9 million in Q2 2025.